Cohance Lifesciences gets USFDA report for Hyderabad unit
Key Highlights
The USFDA has classified the inspection outcome as Voluntary Action Indicated
Cohance Lifesciences received the Establishment Inspection Report from the US Food and Drug Administration for its manufacturing unit in Pashamylaram. The regulator classified the outcome of the inspection as Voluntary Action Indicated. This follows a site visit conducted by the agency earlier this year.
The USFDA inspection of the Hyderabad facility took place between July 27, 2026, and August 5, 2026. Following this assessment, the regulator issued the formal report to the company. The classification of Voluntary Action Indicated means the agency found conditions that require attention but do not warrant strict regulatory action at this time.
Cohance Lifesciences operates as a contract development and manufacturing organization and an active pharmaceutical ingredient platform. The company provides services covering the entire lifecycle of a molecule, ranging from initial development stages through to commercial production. The firm was formerly known as Suven Pharmaceuticals.
Based on company and agency reports. For information only; not investment advice.